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Abstract
Friedreich ataxia (FRDA) is an inherited neurodegenerative disease caused by frataxin (FXN) deficiency. The nervous system
and heart are the most severely affected tissues. However, highly mitochondria-dependent tissues, such as kidney and liver,
are not obviously affected, although the abundance of FXN is normally high in these tissues. In this study we have revealed
two novel FXN isoforms (II and III), which are specifically expressed in affected cerebellum and heart tissues, respectively,
and are functional in vitro and in vivo. Increasing the abundance of the heart-specific isoform III significantly increased the
mitochondrial aconitase activity, while over-expression of the cerebellum-specific isoform II protected against oxidative
damage of Fe-S cluster-containing aconitase. Further, we observed that the protein level of isoform III decreased in FRDA
patient heart, while the mRNA level of isoform II decreased more in FRDA patient cerebellum compared to total FXN mRNA.
Our novel findings are highly relevant to understanding the mechanism of tissue-specific pathology in FRDA.
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Introduction
Frataxin (FXN), a highly conserved protein from bacteria to
humans, is important in the biogenesis of iron-sulfur clusters (ISC),
prosthetic groups allowing essential cellular functions such as
oxidative phosphorylation, enzyme catalysis and gene regulation
(see reviews [1,2]). Reduced expression levels of this protein are
sufficient to induce Friedreich ataxia (FRDA), a relentless and
currently incurable inherited neurodegenerative disease (see
review [3]). Recently many studies suggest that Friedreich ataxia
is an epigenetic disorder (see review [4]) and HDAC inhibitors
correct frataxin deficiency [5,6]. It is well accepted that FXN acts
as an iron-chaperone within the mitochondrial compartment, and
a functional extra-mitochondrial pool of frataxin has also been
observed in various human cell types [7–10]. Not only FXN, but
also other ISC proteins represent a heterogeneous group of
proteins with different functional features and different subcellular
localizations [11–13]. Frataxin is involved in the biosynthesis of
ISC not only within mitochondria [14–17], but also in the extra-
mitochondrial compartment [7] by physically interacting with
ISCS/ISD11 and ISCU, components of the Fe/S cluster assembly
core machinery [7,15–17].
Extra-mitochondrial isoforms of the central components ISCS
and ISCU [12,18] have been identified in human cells. Little is
known about the generation of the extra-mitochondrial FXN in
human cells. It is postulated that the extra-mitochondrial isoform
represents a cytoplasmic redistribution of frataxin after its
mitochondrial processing [7], determined by the molecular size
of the cytosolic and mitochondrial isoforms in an SDS-PAGE gel.
This indirect sizing technique does not identify exact amino-acid-
sequence differences of the N-terminus of FXN, but the observed
extra-mitochondrial isoforms are functional.
Cells derived from FRDA patients have a partial defect in ISC-
containing proteins, with consequent mitochondrial damage
[19,20], lower ATP production, and impaired iron utilization,
leading to mitochondrial iron accumulation [3,21]. The nervous
system and heart are the most severely affected tissues. However,
tissues with a high mitochondrial demand, such as kidney and
liver, are not obviously affected, although the level of FXN in these
tissues is high in healthy individuals (Li K, unpublished data and
[22]). And blood cells from Friedreich ataxia patients harbor
frataxin deficiency without a loss of mitochondrial function [23].
We suspected that the tissue-specific pathology of FRDA might
arise from tissue-specific expression of FXN isoforms and that the
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extra-mitochondrial isoforms might contribute to molecular
pathogenesis.
In this study, we identified two novel tissue specific transcript
variants, encoding two isoforms of FXN (isoform II and III), which
lack the mitochondrial targeting sequence and are therefore
different from the canonical transcript (encoding isoform I). The
three isoforms preferentially localized in different compartments.
Functional assays revealed that isoform I and II protect Fe-S
cluster from oxidative damage, and FXN III acts as a mitochon-
drial Fe-S-biogenesis enhancer. Our findings suggest a direct
mechanism by which FXN deficiency could cause tissue-specific
pathology of Friedreich ataxia.
Results
Identification of the diverse transcripts of human FXN
To study whether previously reported FXN isoforms were
produced from different transcripts, we performed 59-RACE with
RNA isolated from HEK293 cells, in which a reverse primer
(primer 353, sequence see table S1) located in exon 4 was used.
The previously observed extra-mitochondrial FXN isoforms could
differ in the N-terminus of FXN, so we expected that more than
one transcript might be identified. As shown in Figure 1A, we
found 7 rational transcripts, which fell into five categories
depending on the presence or absence of exon 1A/1B, or exon
3: I) the canonical transcript including exon 1 (now designated as
exon1A), 2, 3, 4, and 5; II) transcript without exon 1A, but
containing either exon1B or exon1B that lacks 18 nucleotides
(exon1BD18) from the 59-end of the transcript; III) canonical
transcript that lacks exon 3 (Dexon3); IV) combination of type II
and III; V) canonical transcript that lacks 141 nucleotides at the
very 39-end of exon1A. All these transcripts may be generated
through alternative splicing or exon skipping except that category
II could also be generated through a different transcription start
site. To verify the multiple transcripts in case of the artifacts in cell
line HEK293, we designed the primers to perform reverse-
transcription PCR with commercial total RNA from human
tissues including cerebellum, heart, and skeletal muscle. The
results showed that all tissues expressed the canonical transcript,
whereas heart and cerebellum possessed additional specific bands,
which differed in pattern or amount (Figure 1B) from canonical
one. We also performed Northern analyses with polyA RNA from
HEK293 cells. Multiple FXN bands were observed again
(Figure 1C), similar to previous results [21,22].
In order to find more supportive evidence, we searched
AceView database. Interestingly, we found a diagram that
illustrated comprehensively the alternative transcripts, which are
consistent with our findings, but miss exon1AD141-containing
transcript. The tissues from which the cDNAs were generated are
listed and the correlation between the transcripts identified in this
study and those annotated in AceView database is linked by
spotted lines (Figure 1D).
Localization of the deduced human FXN isoforms
To understand the alternative transcripts of human FXN, we
first compared the isoforms deduced from the transcript variants.
Exon1B/D18-containing transcripts could encode a 135-amino-
acid isoform (135-aa, FXN isoform II, FXN II) of FXN with an
expected molecular size 14.9 kDa, and exon1AD141-containing
variant is predicted to encode a 164-aa isoform (FXN isoform III,
FXN III) of 18.2 kDa. The mature form of canonical isoform (210
aa, FXN isoform I, FXN I), containing N-terminal sequence
SGTLG verified by protein sequencing (Columbia University
Protein Core Facility), has 130 amino acids (from 81st to 210th aa
of the 210-aa precursor) with molecular size 14.2 kDa (Figure 2A).
This size of mature form was validated previously by another two
groups [9,24].
Since there is more than one AUG sequence at the 59-end of
exon1B/D18-containing transcripts, we cloned three DNA frag-
ments, including exon1B- and exon1BD18-containing transcripts
and another that encompassed the second AUG (coding for
methionine, 76th aa of FXN precursor) of human FXN coding
region to the stop codon, to see if the first two encode a protein
same as the last one as predicted. For simplicity, we designated the
three construct-encoded proteins as FXN1B, FXN1BD18, and
FXN76, respectively. Western results showed that the three
constructs encoded the same size of FXN proteins (Figure 2B).
Hereafter, FXN II represents exon1B/D18-containing transcript-
encoded FXN and FXN76. Next, the distinct N-termini of FXN
isoforms were aligned (Figure 2C). Full-length FXN I contains
a mitochondrial targeting sequence, which is entirely lost in FXN
II and partially absent in FXN III. To determine the cellular
localization of the isoforms, we constructed plasmids to express
FXN-GFP fusion proteins. As expected, FXN I located pre-
dominantly in the mitochondria. However, FXN II and III located
mainly in the cytosol and nucleus, respectively (Figure 2D). Since
the negative control, GFP alone, located mainly in the nucleus, we
could not distinguish FXN-isoform localization from the effect of
GFP itself although the distinction was clear for FXN I. We then
tagged FXN with-myc to detect the localization of FXN isoforms,
since the molecular size of myc-tag is much smaller than that of
GFP. Again, we observed FXN I in the mitochondria, while FXN
II located dominantly in the cytosol and FXN III in the nucleus
(Figure S1).
Tissue-specific expression of human FXN II in the central
nervous system (CNS) and FXN III in heart
To verify the tissue-specific transcripts, we analyzed a variety of
tissues, fibroblasts and lymphoblasts derived from healthy controls
or FRDA patients by quantitative real-time PCR (qPCR). As
shown previously [21], patient cells expressed much lower mRNA
levels of FXN than control cells, and normal heart expressed the
highest levels of FXN among the tested tissues (Figure 3A, left
panel and [22]). In agreement with the data shown in Figure 1B,
cerebellum showed the highest abundance of exon 1B-containing
transcripts compared to other tissues such as heart and skeletal
muscle (Figure 3A, right panel), although it represented only about
1.25% of total transcripts (Figure 3B). When comparing the most
affected CNS tissues including cerebellum, spinal cord and dorsal
root ganglion, we found much higher expression levels of exon1B-
containing FXN transcript in CNS tissues than in other tissues
(Figure 3B).
To assess whether the levels of different transcripts changed or
not in FRDA patients compared with the healthy controls, we
performed qPCR to analyze the mRNA levels of FXN in
cerebellum and heart, two of the most affected tissues in FRDA
patients. The results showed that the overall mRNA levels of FXN
decreased, consistent with a previous study [22], while expression
of the canonical transcript of FXN was more diminished in heart
(21.9% of WT levels) than in cerebellum (75.5% of WT levels),
and that of the exon1B-containing transcript diminished more
(51.6% of WT levels) than the exon1A-containing transcript
(75.5% of WT levels) in cerebellum (Figure 3C). The exon1B-
containing transcript in heart was below levels of detection. These
findings illustrated that expression of the exon 1B-containing
transcript was limited to, and significantly reduced in, clinically
relevant FRDA tissues, such as the cerebellum. Our attempts to
Tissue Specific Expression of Human FXN
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similarly quantify the exon1AD141-containing transcript in heart
tissue were hampered due to lack of suitable unique sequences.
To detect the existence of protein isoforms encoded by the
canonical transcript and the two novel transcripts, we performed
immunoprecipitation (IP) and western blots with cell lysates from
FRDA patient heart tissue or lymphoblast cells. Figure 3D shows
that there was one novel band (* marked) in the control heart
lysate in addition to the mature mitochondrial form (Figure 3D).
The size of this novel band is slightly larger than the mature form,
but smaller than the expected size of FXN III. It might be the
degraded FXN III because of the instability of FXN III (see below
and discussion). Unfortunately, insufficient human cerebellum
tissue was available for IP to identify the endogenous CNS
isoforms.
Functional isoforms of human FXN in vitro
To directly assess whether the new isoforms were functional, we
used enzymatic assays based on the fact that IRP1 becomes
a functional aconitase upon acquisition of a [4Fe-4S] cluster.
Three FXN isoforms were overexpressed in E. coli and purified as
shown in Figure 4A. FXN I and II with expected sizes 14.2 and
14.9 kDa, respectively, ran unusually in a SDS-PAGE gel. FXN I,
supposed to run faster than FXN II, actually ran slightly slower,
which phenomenon was observed previously [24]. FXN III with
expected size 18.0 kDa showed two additional smaller degraded
bands, identified by mass spectrometry. Its instability will be
discussed in Discussion. To test whether FXN isoforms were able
to form a core complex with ISCU, ISCS/ISD11, we also purified
the components including human mitochondrial mature forms of
Figure 1. Identification of the diverse transcripts of human FXN. (A) Schematic diagram of transcripts of human FXN. One arrow shows the
position of the primer for reverse transcription, locating in exon 4 used for 59-RACE with RNA from HEK293 cells. PCR products were sequenced to
identify the transcripts. Exon1A is the first canonical exon (only the size of coding region shown); exon1Ag141, exon1A missing the last 141
nucleotides; exon1B, the novel exon 1 locating in the first intron; exon1Bg18, missing 18 nucleotides near the 59-end of exon1B; gexon3, transcript
missing exon3. (B) Transcripts of human FXN dectected with RT-PCR showed tissue-specific expression pattern. C: cerebellum; H: heart; M: skeletal
muscle. (C) Diverse transcripts may exist in cells, unveiled by Northern blot. (D) Potential FXN transcripts from AceView database, verified when
human tissues or cell lines were used. Here are only shown transcripts a, b, d, e, and f. See http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.
cgi?c = geneid&org = 9606&l = 2395. Flagged ones (a,b,d) are annotated to be validated. The correlation between the mRNA identified in this study
and those annotated in AceView database is linked by spotted lines. Transcript a and b are not distinguishable and are considered as canonical ones
because the primer used for 59-RACE positions within exon 4 of human FXN. Scale: 200 bp.
doi:10.1371/journal.pone.0047847.g001
Tissue Specific Expression of Human FXN
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ISCU and ISCS/ISD11. We found that these four core
components were able to form a complex as shown in Figure 4B,
consistent with recently reported results [14–16]. Two-component
(ISCU+ISCS) or three-component (ISCU+ISCS/ISD11) com-
plexes were easily detected (Figure S2 and Figure 4B, best
visualized in later fractions of the middle panel), similar to
Figure 2. Comparison of putative human FXN isoforms. (A) Schematic diagram of the putative FXN isoforms expressed in human heart or
cerebellum. (B) Western blot showing that exon1B-containing transcript variant encoded a second-AUG initiated isoform FXN76, i.e., FXN II. (C)
Protein alignment of FXN isoform I, II, III, encoded by transcripts containing canonical exon 1A, exon1B/exon1Bg18, and exon1Ag141, respectively.
Hereafter, exon1B replaces exon1B/exon1Bg18. This figure only shows the N-termini of FXN. In the upper panel methionine in the middle of the
sequence of FXN is marked with an asterisk, which may be the start codon of the novel FXN transcript containing exon 1B. Underlined amino acid
sequences in the bottom panel are identical between the isoform I and III. (D) Cellular localization of different isoforms of human FXN. eGFP only: in
nucleus; FXN I-eGFP: in mitochondria; FXN II-eGFP: in cytosol and nucleus; FXN III-eGFP: more in nucleus than in cytosol.
doi:10.1371/journal.pone.0047847.g002
Tissue Specific Expression of Human FXN
PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e47847
complexes of these proteins previously identified in vitro and in vivo
in mitochondria and cytosol [11,12]. Then we asked whether this
complex was relevant to facilitate Fe-S cluster assembly. Fe-S
cluster was monitored during the assembly and an in-gel aconitase
assay was performed to detect the assembled transferred Fe-S.
Surprisingly, recording of Fe-S cluster assembly in the presence of
FXN III failed due to the obvious precipitation in the reaction, so
Figure 4C only shows the kinetics in the presence of FXN I and II.
Isoform I showed higher activity than FXN II although their
efficiency was comparable. In-gel aconitase assays revealed that
three FXN isoforms facilitated Fe-S cluster assembly with an
efficiency order of FXN III as the highest, then FXN I in the
middle, and then FXN II as the least (Figure 4D), which was
consistent with spectrum scan data after iron sulfur cluster
assembly with relative low concentration of FXN isoforms
(2 mM, Figure S3A).
Functional evaluation of human FXN isoforms in cell lines
To further characterize the human FXN isoforms, we expressed
the isoforms in different cell lines including HEK293, HeLa, and
N2a. Any effect of FXN isoforms on Fe-S cluster biogenesis, or on
iron metabolism, could be monitored by the in-gel assay because
both cytosolic (c-aco) and mitochondrial (m-aco) aconitases
function as sensors of Fe-S cluster biogenesis in both compart-
ments of mammalian cells. Therefore, this assay was performed to
evaluate the function of FXN isoforms. Over-expression of full-
length (FXN I-m) and mature (FXN I-c) isoform I and FXN II all
showed similar negative effects on aconitase activities, probably
due to the general toxicity, in agreement with the observation in
which the mature form of FXN without a mitochondrial targeting
sequence could fully replace full-length FXN [7,10,25]. However,
the adverse effect was only rather mild in HEK293 cells, but
severe in HeLa and N2a cells. More interestingly, c-aco activities
were much more deleteriously affected than m-aco activities
regardless of the localization of the overexpressed FXN isoforms
(Figure 5A). Such negative effects of over-expressed human and
fruit fly FXN have also recently been reported [26]. In contrast,
FXN III over-expression increased both m-aco and c-aco activities
(greater than 2 folds) in all tested cell lines (Figure 5A, 5C),
consistent with the in vitro assay (Figure 4D), even though the
Figure 3. Novel transcripts and/or isoforms of human FXN showed the tissue-specific expression pattern. (A) Quantification of frataxin
transcripts by qRT-PCR. Total: total mRNA of FXN, exon1B: exon1B-containing transcript of FXN. Human tissues including cerebellum, heart, and
skeletal muscle and cells including fibroblasts (fibro-) and lymphoblasts (lympho-) derived from healthy controls (C) and FRDA patients (P) were
analyzed. (B) Ratio of transcripts containing exon1B to total FXN in human tissues. (C) Quantification of FXN transcripts in FRDA patient heart and
cerebellum, compared to healthy controls. No standard deviation due to 2–3 samples of each tissue from controls or patients is provided. Values are
the relative means. (D) Immunoprecipitation (IP) of human FXN in a healthy and FA patient heart and patient lymphoblast cells. Lysate before IP was
loaded to run a SDS-PAGE gel and then to be stained with Coomassie as a sample control for comparison. Left panel: IP-Western, anti-FXN; right
panel: Coomassie-stain sample control. *: a novel heart-bearing FXN band.
doi:10.1371/journal.pone.0047847.g003
Tissue Specific Expression of Human FXN
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increased abundance of this isoform was the least compared with
that of other two isoforms (Figure 5A, a-myc signal in the last two
lanes for N2a cells), suggesting that a slight decrease of heart-
specific FXN III may have significant impairment effect on
aconitase activities in heart.
Treatment of FRDA patients with antioxidants to counteract
oxidative stress has been shown to improve neuronal impairment
[27]. To further analyze cerebellum-specific FXN II, we first
overexpressed FXN isoforms, then treated the cells with hydrogen
peroxide (H2O2) for 1 hour. Aconitase activities were assayed as
shown in Figure 5B. Clearly, all of the human frataxin isoforms
largely protected the Fe-S-containing aconitase from oxidative
damage, particularly the c-aco activity (Figure 5B, 5D), indicating
that FXN prevented disassembly of the Fe-S cluster in c-aco to
generate apo-IRP1 after H2O2 treatment. Relatively, m-aco
activities were much less affected by the H2O2 treatment,
suggesting that m-aco is less accessible than c-aco to the effect of
H2O2, in agreement with the previous observation [13]. In-
terestingly, both full-length and mature forms of FXN I, the
former dominantly localized in mitochondria and the latter in
cytosol (Figure 2D), comparably protected both m-aco and c-aco
activities after H2O2 treatment. The protection effect of isoform
II, localized largely in cytosol, from disassembly of Fe-S cluster of
c-aco was relatively minor. However, the c-aco activities of IRP1
had returned to baseline levels within 1 hr after removal of H2O2,
indicating robust in-vivo repair/regeneration of the [4Fe-4S]
cluster, which was then transferred to apo-IRP1 to gain the
aconitase activity. In contrast, isoform III did not efficiently restore
c-aco activity within the tested time. Taken together, our results
suggest that FXN isoform II, the cerebellum-specific variant,
Figure 4. Functional human FXN isoforms facilitating Fe-S cluster assembly in vitro. (A) FXN isoforms were expressed in E. coli and purified
to run a SDS-PAGE gel, followed by Coomassie staining. (B) Each of the three FXN isoforms could form a complex with other three essential
components (ISCS/ISD11, ISCU) of Fe-S cluster assembly in vitro. Purified proteins FXN, ISCU, and ISCS/ISD11 were mixed and incubated for 1 hour
anaerobically, and then subjected to size exclusion column. The collected fractions were run in SDS-PAGE gels as shown here. (C) Fe-S cluster
assembly profile at 456 nm within 90 min. (D) In-gel aconitase assay of IRP1 after incubation of apo-IRP1 with assembled Fe-S cluster by the complex
of four components including FXN, ISCS/ISD11, and ISCU.
doi:10.1371/journal.pone.0047847.g004
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Figure 5. Functional assays of human FXN isoforms in cell lines. (A) Each of FXN isoforms was over-expressed in cell lines HEK293, HeLa, and
N2a, respectively. Harvested cells were lysed 48 hours post-transfection for aconitase assay and western blot (see Methods and Materials). For each
cell line, the top two panels are aconitase assays; the rest are Western blot results. FXN I-m, full-length mitochondria-localized FXN isoform I; FXN I-c,
mature form of FXN isoform I, cytosol-localized. m-aco: activities of mitochondrial aconitase; c-aco: activities of cytosolic aconitase, which is Fe-S
Tissue Specific Expression of Human FXN
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functions more to protect cells from oxidative damage by efficient
repair of Fe-S clusters in the cytosol, whereas FXN isoform III, the
heart-specific variant, focuses more on Fe-S cluster biogenesis for
m-aco activity, which may be physiologically relevant (see
discussion).
Discussion
In this study we have demonstrated that frataxin has various
isoforms in addition to the canonical form. We have further shown
that at least two of the novel isoforms are expressed in a tissue-
specific manner. Using a number of molecular methods, we
demonstrate that these two isoforms are functional in vitro, forming
a complex with three other core-components of the iron-sulfur
cluster assembly machinery, ISCU, ISCS, and ISD11, to facilitate
Fe-S cluster assembly. A small increase in the abundance of the
heart-specific FXN isoform III in cell lines significantly increased
the aconitase activity, particularly that of m-aco. In contrast, over
expression of cerebellum-specific FXN isoform II protected against
oxidative damage of aconitase, particularly c-aco. More impor-
tantly, we observed that the levels of FXN, not only the canonical
isoform I, but also the newly found isoform III, significantly
decreased in FRDA patient heart, while the levels of the isoform-II
transcript were comparatively more reduced in FRDA patient
cerebellum than that of total FXN mRNA. Our novel findings
reveal a possible mechanism for the tissue-specific pathology of
Friedreich ataxia.
The in vitro heterogeneously expressed FXN III displayed
different stability from FXN I and II. FXN III was unstable and
easily degraded during purification (Figure 4A), whereas FXN I or
II always showed a single band in SDS-PAGE gel. This
phenomenon was coincidently observed previously by Cowan
and his colleagues [28,29]. FXN investigated in above mentioned
paper corresponds to residues 56–210 of human FXN, while FXN
III involved in this study missed 47 amino acids from 9th to 55th.
Very likely, FXN III shares the similar mechanism of ‘‘iron
mediated self-cleavage’’ to be degraded in vitro. We confirmed that
EDTA addition could prevent FXN III from degradation (data not
shown). This might explain that heart-specific FXN III showed
a smaller size than expected (Figure 3D).
The occurrence of extra-mitochondrial FXN has been debated
since Cocozza and colleagues first reported this finding [7].
Subsequent studies have followed up to investigate the potential
functions of extra-mitochondrial FXN [8,10,25,30]. Mechanisti-
cally, extra-mitochondrial FXN has only been described by
comparing the sizes of FXN proteins in SDS-PAGE gels [7,10].
Here we demonstrate a mechanism of how cytosolic FXN can be
generated. Based on the speculation that the difference might be at
the very end of N-terminus due to the distinct location of the
isoform, we found transcript variants of human FXN, two of which
encoded isoform II and III, both lacking the mitochondrial
signaling peptide. Accordingly, extra-mitochondrial locations were
confirmed for both isoforms. And the abundance of FXN transcript
generating isoform I and II is reduced in the cerebellum of FRDA
patients although the reduction level (75.5% and 51.6% of the
control levels, respectively) is higher than that reported previously
(10–30%) (see review [31]). We could not well explain this
divergence from other literature, whereas the expression levels of
control FXN varies largely (threefold) in a group of 50 normal
people [32] and the reported levels of patient FXN were averaged,
mostly in peripheral blood mononuclear cells [23,33,34] or
fibroblasts/lymphocytes [21,35],rarely quantified in the affected
tissues [36,37]. The number of the patients in our study is not
enough due to the scarcity of the tissues so that the percentage of
75.5% or 51.6% is not a statistical mean of FXN levels of patients.
Obviously, the real statistical mean needs to be acquired with
a large number of healthy controls and FRDA patients.
Isoform II and III localized with cellular compartmental
preference for the cytosol or nucleus, respectively, whereas the
canonical isoform I localized to mitochondria. In general, all three
isoforms displayed protection against oxidative damage of
aconitase, particularly that of c-aco, when challenge with H2O2.
The isoform II protective effect on c-aco could be explained by its
cytosolic localization and the isoform I protective effect by its
minor cytosolic distribution after over expression. Intriguingly,
isoform III, which localizes more in the nucleus than in the cytosol,
can significantly enhance mitochondrial aconitase activity. This
apparent lack of correlation between localization and functional
phenotype of isoform III requires further investigation. However,
its functional effect and its tissue-specific expression pattern agree
with the pathology of affected heart tissue in FRDA patients.
Heart, which has a high energy need in accordance with a high
rate of Fe-S biogenesis, is one of the tissues maintaining the highest
mitochondrial aconitase activity [38]. This activity is deficient in
endomyocardial biopsies of FRDA patients, together with de-
ficiency in the activities of the Fe-S cluster-containing subunits of
mitochondrial respiratory complexes I, II and III [39,40]. On the
other hand, heart is very sensitive to overloaded iron [41]. Isoform
III might be a good mediator to incorporate iron to diminish the
toxicity of the overloaded iron in normal heart cells and to
promote Fe-S cluster biogenesis. Our in vitro data provided
evidence in favor of the higher iron binding activities of isoform III
than isoform I and II (Figure S3B), in agreement with its high
capacity to enhance Fe-S biogenesis (Figure 4D, 5, and S3A).
Therefore, even slightly decreased expression of isoform-III may
raise the toxicity of overloaded iron in FRDA patients, consistent
with ROS production via Fenton chemistry [42].
In summary, our results suggest a novel mechanism for the
tissue-specific pathology of Friedreich ataxia. If the existence of
a homolog of one of the human FXN isoforms in mouse tissues
could be confirmed, using the above findings, a new ‘Fxn isoform-
specific defective’ mouse model may be considered to further study
FRDA disease mechanisms and therapy in the future.
Materials and Methods
Ethics Statement for Human tissues and RNAs
Human tissues were obtained from autopsies of two FRDA
patients (47 year-old Caucasian male with GAA repeats of 750/
750 and 36 year-old Caucasian female with GAA repeats of 700/
700) and two non-FRDA individuals (80 year-old Caucasian male
and 82 year-old Caucasian female), in accordance with UK
Human Tissue Authority ethical guidelines. Approval has been
obtained from the Brunel University School of Health Sciences
and Social Care Research Ethics Committee and the Brunel
University Human Tissue Act Compliance Committee. The
FRDA tissues were obtained from Ataxia UK and non-FRDA
tissues were obtained from NDRI (The National Disease Research
containing iron regulatory protein 1(IRP1); TfR: transferrin receptor 1. (B) Hydrogen peroxide (400 mM H2O2) challenge on HeLa cells, in which FXN
isoforms were expressed as indicated. Aconitase activities were chased within 2 hours. (C) Quantification data of left panel of Figure B. (D)
Quantification data of right panel of Figure B. Both (C) and (D) are expressed as mean 6 SD from three independent experiments.
doi:10.1371/journal.pone.0047847.g005
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Interchange) and these organizations hold the details of written
consent.
Cell culture and transfection
Cell lines HEK293, N2a, HeLa were purchased from ATCC
(Manassas, VA). Fibroblasts or lymphoblasts derived from healthy
control (GM08399) or non-affected carrier (GM15849) and
Friedreich ataxia patients (GM03665, GM15850) were obtained
from the Coriell Cell Repository (Camden, NJ). HEK293 cells
were grown in alpha-modified MEM medium (Sigma, St. Louis,
MO), N2a in DMEM, fibroblasts in MEM and lymphoblasts in
RPMI 1640 medium, all supplemented with 10% fetal calf serum
and 2 mM glutamine (Invitrogen, Carlsbad, CA). For transfection,
Fugene 6/HD (Roche, Indianapolis, IN) or lipofectmin 2000
(Invitrogen) was used according to the supplier’s manuals.
DNA manipulation
Plasmid constructs expressing FXN isoforms were generated as
following. The PCR products of FXN fragments were cloned into
plasmid pcDNA3.1(2) with XhoI and HindIII sites or into plasmid
pET24a(+) with NdeI and XhoI sites or into plasmid peGFP-N1
with XhoI and BamHI sites. Plasmid DNA was isolated with
Qiagen miniprep or midiprep kits (Valencia, CA) as needed. The
right clones were confirmed by sequencing.
A plasmid coexpressing ISCS, which misses the first 55 amino
acids of human mitochondrial ISCS precursor (previously de-
scribed as NFS1D1-55 [30]), and ISD11 was generated as follows.
By PCR, the restriction sites BglII and XhoI were introduced for
cloning the PCR products of ISCS into pACYCDuet-1 (Novagen).
The resulting plasmid was designated as pZM90a. In addition, the
restriction sites NcoI and HindIII were introduced into the ISD11
cDNA for cloning into the second multiple cloning site of
pZM90a. The resulting plasmid was designated as pZM90b.
All primers used for the constructs are listed in table S1.
Protein expression, purification, size exclusion
chromatography, and Fe-S assembly
Three FXN isoforms and ISCU were expressed in E. coli strain
BL21(DE3) and purified as described previously with some
modification [11]. For FXN III, EDTA (5 mM) was added into
the lysis buffer before lysing the E. coli cells. The concentration of
EDTA was then kept 1 mM during the whole purification
procedure. The ISCS and ISD11 were heterologously co-
expressed in E. coli and purified as described previously [11,30].
For co-expression of ISCU and ISCS or ISCU and ISCS+ISD11,
either E. coli BL21(DE3) or E. coli CL100(DE3) [43] cells lacking
endogenous IscS (DiscS) were used.
Purified ISCS/ISD11, ISCU, and FXN isoform were incubated
in an anaerobic chamber in a volume of 500 ml with a molar ratio
of 1:1:1 for 1 h at room temperature, then immediately applied
onto Superdex200 column equilibrated with buffer containing
50 mM Tris, 200 mM NaCl, and 5 mM PLP (pH 8.0). The
500 ml-elution fractions were analyzed by SDS-PAGE.
Fe-S assembly was carried out as described previously [11].
Quantitative real-time PCR (qPCR), reverse transcriptional
PCR (RT-PCR) and Northern blot analysis
Total RNA or mRNA of human tissues were isolated with
Trizol (Invitrogen) or purchased from Ambion (Austin, TX).
Reverse transcription was performed with RevertAidTM First
Strand cDNA Synthesis Kit according to manufacturer’s in-
struction (Fermentas, ShenZhen city, Guangdong province,
China). The comparative Ct method with SYBR Green was
conducted with the ABI 7000 Real-Time PCR System (Applied
Biosystems, Foster City, CA). Endogenous GAPDH was used as
an internal control for normalization. When mRNA levels of
different human tissues were tested, 18S RNA was used as an
internal control. All primers used for RT-PCR or qPCR are listed
in Table S1.
Northern hybridization was carried out and the blot was
exposed to PhosphoImage screen and detected with Typhoon
9200 (GE Healthcare). Full-length FXN fragment covering the
coding region was labeled with [32P]-ATP (Perkin Elmer,
Waltham, MA) as a probe. Labeled GAPDH was used as an
internal control.
59 Rapid Analysis of cDNA Ends Derived from Full Length
RNA (RACE)
59-RACE was performed using the GeneRacerTM kit (Invitro-
gen) according to the manufacturer’s instructions. Reverse
transcription with random hexamers was used to synthesize
cDNA. To obtain 59 ends, the first strand cDNA was amplified
using a FXN specific primer 353 (see table S1) and the
GeneRacerTM 59 primer. The RACE PCR product was
visualized on a 1.5% agarose gel, purified and cloned into the
pCR 4-TOPO vector using the TOPO TA cloning kit (Invitro-
gen). Totally 40 clones were picked for plasmid isolation and
further for sequencing.
Immunoprecipitation and western blotting Analysis
Immunoprecipitation was performed as described previously
[21]. In brief, cell lysate was cleaned by incubation with magnetic
beads coupled with horseradish peroxidase linked anti-mouse IgG
(Invitrogen), then subjected to incubation with FXN antibody
(MitoSciences, Eugene, Oregon) coupled magnetic beads. After
2 hours incubation, the beads were washed. The proteins were
eluted from the beads for Western.
Proteins were resolved in 12% NUPAGE gels (Invitrogen, cat#
NP0342box) and transferred onto nitrocellulose membranes
(Invitrogen, cat# IB3010-01). Primary antibodies used were
rabbit anti-IRP1 [44] and anti-Ferritin (US Biological Inc.,
Swampscott, MA), mouse anti-tubulin (Abcam, Cambridge,
MA), anti-transferrin receptor (Zymed, San Francisco, CA), and
anti-frataxin (MitoScience). The mature frataxin form (,14 kDa)
was quantified for comparison when needed. Western blot band
intensities were quantified using program ImageJ. Any change of
the intensities was compared with the controls, which value was set
as 1.
In-gel aconitase activity assays
In-gel aconitase activity assays were performed as described
previously [13]. Related chemicals used were purchased from
Sigma (St Louis, MO).
Determination of protein localization
FXN constructs were generated by ligation of FXN fragment
with peGFP-N1 (Clontech) or pcDNA3.1-myc (self made by
adding myc-tag DNA fragment into multiple cloning site of
pcDNA3.1(2)). C-terminal GFP- or myc-tagged FXN fusion
protein was expressed after transfection. Mitotracker was pur-
chased from Sigma for mitochondrial staining. Localization of
FXN-GFP or FXN-myc was determined with Confocal (FV 10i-o,
Olympus) by either direct visualizing fluorescence (GFP) or
immunofluoresence staining (-myc).
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Statistical analysis
All data are representative of three or more independent
experiments. Due to the scarcity of the affected tissues, only 2–3
samples for each tissue were used in this study so that direct
comparison between patients and control was conducted with
mean only without standard deviation (SD). Statistical analyses for
function assays of each isoform were performed by Student’s t test
for paired samples (see http://danielsoper.com/statcalc3/default.
aspx) and expressed as mean 6 SD.
Supporting Information
Figure S1 Subcellular localization of human FXN iso-
forms. C-terminal myc-tagged FXN isoforms were expressed in
HEK293 cells. The localization was determined by Confocal.
(TIF)
Figure S2 Two-component (ISCU+ISCS, panel 1,3) or
three-component(ISCU+ISCS/ISD11, panel 4)complexes
were detected in a single NI-NTA affinity purification
step. His-tagged human ISCU was over-expressed and purified
with NI-NTA resin. Endogenous IscS of E. coli (panel 1, 4) and
untagged recombinant human ISCS with (panel 4) or without
ISD11 (panel 3) could be co-purified with human ISCU,
confirmed by mass spectrometry. BL21(DE3): E. coli strain for
over-expression of recombinant protein; CL100(DE3): E. coli strain
with iscS deletion (DiscS).
(TIF)
Figure S3 High iron binding activity of FXN III is
correlated with its high capacity for iron-sulfur cluster
assembly. A FXN III is the most efficient for iron sulfur cluster
assembly. Anaerobic iron-sulfur cluster assembly in vitro was
performed with or without FXN isoforms and the kinetic spectrum
was scanned with 15 min interval within 90 min. B Iron content
was determined by inductively coupled plasma atomic emission
spectroscopy. E. coli were cultured in LB growth medium with or
without iron addition for FXN over-expression. FXN proteins
were purified and subject to iron content determination.
(TIF)
Table S1 Primer pairs used in this study.
(DOC)
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